PAGE：70-76

    Clinical and experimental study of cough and asthma cataplasma(咳喘巴布膏) on the relaxed interim of bronchial asthma

    CHU Dong-ning, LOU Jin-tu, JIA Gui-luan, MAO Lin-yan， CHENG Guo-jun， WANG Xu, SHEN Guo-xing， DU Qin, ZHAN Yong-xiang, YU Ding-zhen， YU Xi-lin

    Zhejiang Youth Hospital, Hangzhou 310016, Zhejiang, China

    Objective： To study the clinical effect of cough and asthma cataplasma(咳喘巴布膏， CAC) in the relaxed interim of bronchial asthma and therapeutical mechanism. Methods： Using a prospective randomized comparison method, 62 patients with relaxed interim of bronchial asthma were randomly divided into two groups: cataplasma group (32 patients, added CAC) and control group (30 patients). The treatment of inhaling anti-inflammatory and antiasthmatic drugs were used in two groups, the course of treatment was one month. Corresponding experimental study was conducted. Results： The short-term therapy effect showed that the clinical controlling effect of cataplasma group reaches 93.75%, which was significantly superior to the 53.33% of control group. The cataplasma group improved lung function significantly, reduced eosinophil (EOS) and eosinophil cationic protein (ECP), which were all better than those of control group. The inhalation amount of beclomethasone dipropionate and salbutamol in cataplasma group was much less than that of the control group. The local skin stimulation of cataplasma and side-response were not significantly. The long-term effect showed that the bouts of cold and asthma grade in the two groups were all reduced significantly. The non-incidence rate in one year of cataplasma group reached 62.50%, which was much higher than 33.33% of the control group. The follow-up drug usage rates of the cataplasma group were 46.88%, which was much less than 60.00% of the control group. Experimental study showed that the inflammable cells of bronchoalveolar lavage fluid (BALF) in cataplasma group reduced significantly than those of the model group; mastocyte and EOS in the pulmonary organization reduced significantly under the microscope. Conclusion： It shows that cough and asthma cataplasma is safe and effective. It has specific effect on the relaxed interim of bronchial asthma. It can significantly ameliorate chronic inflammation in bronchus and reduce high reactivity of bronchus. It can reduce infiltration of inflammatory cells in the pulmonary organization on model of the asthma cavy, control release of chemi-dielectric in inflammable cells, and assume the effect like glucocorticoid. ......